Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

Landmark Phase III Trial Finds Cell Therapy Slows Muscle Decline in Advanced DMD

Published

on

Duchenne muscular dystrophy (DMD) is an X-linked genetic disease that causes the muscles—including the heart—to gradually weaken and waste away. Affecting almost exclusively boys and young men, most patients lose the ability to walk as the disease progresses and come to depend on their arms and hands for everyday tasks and independence. There is no cure.

Deramiocel, a heart-derived cellular therapy consisting of human allogeneic cardiosphere-derived cells, improved cardiac and skeletal muscle function in Phase I–II studies of DMD. Now, a new study reporting on Phase III trial data shows that deramiocel could slow muscle weakening in boys and young men with advanced DMD, and may also slow heart damage in those who already have heart muscle disease.

These Phase III clinical trial data are published in The Lancet in the paper, “Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial.”

This report is the first Phase III trial of a cell therapy made from donor cells and administered through the bloodstream to treat a genetic disease, and the first such trial in boys and young men whose DMD is already advanced.

The HOPE-3 trial involves 106 boys and young men aged 10 to 22 with advanced DMD, who were treated at 20 trial sites across the U.S. They were randomly assigned to receive either deramiocel (54 people) or a placebo (52 people), given as a drip into the bloodstream every three months for a year at an outpatient clinic.

After one year, participants given deramiocel were losing the use of their arms more slowly than those given the placebo. Their overall arm movement declined about 54% more slowly than in the placebo group, and their elbow movement about 65% more slowly. Across all participants, the therapy made no clear difference to how well the heart pumped blood. Among the 64 participants who already had heart muscle disease and had suitable heart scans, heart function was better preserved with deramiocel than with placebo. In a smaller group of 22 participants whose scans could be compared before and after treatment, deramiocel was also linked to less spread of heart scarring, but further research is needed to confirm this finding.

The therapy was generally safe, and no deaths were reported during the trial. Allergic-type reactions were more common with deramiocel (42%) than with placebo (15%). Almost all side effects were mild or moderate and cleared up within a day or two. The most common were headache, cough, fever, nausea, and a fast heartbeat.

The authors say deramiocel has the potential to help people with any type of DMD mutation, because it targets the swelling and scarring the disease causes in the muscles rather than the gene mutation itself. Heart problems are a major cause of death in DMD, and the authors call for further studies to find out whether the heart benefits seen in this trial help people live longer.

The U.S. Food and Drug Administration (FDA) is scheduled to discuss deramiocel at an advisory committee meeting on July 29, 2026, with a decision on whether to approve the therapy expected by August 22, 2026.

The post Landmark Phase III Trial Finds Cell Therapy Slows Muscle Decline in Advanced DMD appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

New webinar: Tackling drug discovery challenges in cancer research

Published

on

Cancer cells

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.

You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.

Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.

Q&A with the speakers follows the presentations.

Register for free now.

The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).

Continue Reading

Uncategorized

Psilocybin proves promising in neuropathic pain mouse study

Published

on

Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.

Continue Reading

Uncategorized

New Spectrometry Technique Could Aid Formulation Development

New Spectrometry Technique Could Aid Formulation Development

Published

on

A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.

According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.

“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”

Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.

The challenge is understanding the link between these things within a heterogeneous sample, he says.

To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.

He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.

Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.

Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.

The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Trending

Helixgate Biotech Review July Issue QR CodeScan to Read